
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
galectin-6 CRISPR/Cas9 KO Plasmid (m) | sc-421418 | 20 µg | $397.00 |
Mouse Lgals6 encodes galectin-6, a β-galactoside–binding lectin implicated in carbohydrate-dependent recognition events at the cell surface and in the extracellular milieu. As a member of the galectin family, galectin-6 can influence cell–cell and cell–matrix interactions, glycoprotein lattice organization, and downstream processes such as epithelial barrier regulation and immune cell signaling. Galectin-driven pathways are commonly linked to modulation of inflammation, leukocyte recruitment, and tissue remodeling through interactions with glycosylated receptors and extracellular matrix components. Dysregulated lectin–glycan signaling has been associated with inflammatory and fibrotic phenotypes in multiple tissues, making Lgals6 a relevant target for mechanistic studies of mucosal immunobiology and microenvironmental regulation.
galectin-6 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Lgals6 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Lgals6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Lgals6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish galectin-6 protein expression.
This CRISPR knockout system enables efficient generation of Lgals6-deficient cell models for investigation of galectin-6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.